Discovery and technical validation of high-performance methylated DNA markers for the detection of cervical lesions at risk of malignant progression in low- and middle-income countries.

Autor: Fackler MJ; Women's Malignancies Program, Department of Oncology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Rm 144, CRB1, Baltimore, MD, 21231, USA., Pleas M; Women's Malignancies Program, Department of Oncology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Rm 144, CRB1, Baltimore, MD, 21231, USA., Li Y; Women's Malignancies Program, Department of Oncology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Rm 144, CRB1, Baltimore, MD, 21231, USA., Soni A; Women's Malignancies Program, Department of Oncology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Rm 144, CRB1, Baltimore, MD, 21231, USA., Xing D; Women's Malignancies Program, Department of Oncology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Rm 144, CRB1, Baltimore, MD, 21231, USA., Cope L; Women's Malignancies Program, Department of Oncology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Rm 144, CRB1, Baltimore, MD, 21231, USA., Ali S; Division of Cytopathology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Van Le Q; Hanoi Medical University, National Cancer Hospital, Hanoi, Vietnam., Van Nguyen C; Department of Quansu Pathology, National Cancer Hospital, Hanoi, Vietnam., Pham HT; Department of Quansu Pathology, National Cancer Hospital, Hanoi, Vietnam., Duong LM; Department of Quansu Pathology, National Cancer Hospital, Hanoi, Vietnam., Vanden Berg E; Department of Anatomical Pathology, Faculty of Health Sciences, University of the Witwatersrand/National Health Laboratory Service, Johannesburg, South Africa., Wadee R; Department of Anatomical Pathology, Faculty of Health Sciences, University of the Witwatersrand/National Health Laboratory Service, Johannesburg, South Africa., Michelow P; Department of Anatomical Pathology, Faculty of Health Sciences, University of the Witwatersrand/National Health Laboratory Service, Johannesburg, South Africa., Chen WC; National Cancer Registry, National Health Laboratory Service, Johannesburg, South Africa.; Strengthening Oncology Services Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Joffe M; Strengthening Oncology Services Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Fjeldbo CS; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Lyng H; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Department of Physics, University of Oslo, Oslo, Norway., Sukumar S; Women's Malignancies Program, Department of Oncology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Rm 144, CRB1, Baltimore, MD, 21231, USA. saras@jhmi.edu.

Publikováno v: Clinical epigenetics [Clin Epigenetics] 2024 Apr 20; Vol. 16 (1), pp. 56. Date of Electronic Publication: 2024 Apr 20.

ALDH1A1 drives prostate cancer metastases and radioresistance by interplay with AR- and RAR-dependent transcription.

Autor: Gorodetska I; OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany., Offermann A; Institute of Pathology, University Hospital Schleswig-Holstein, Luebeck, Germany; Pathology, Research Center Borstel, Leibniz Lung Center, Borstel, Germany., Püschel J; OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany., Lukiyanchuk V; OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany., Gaete D; Institute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, Dresden, Germany., Kurzyukova A; Technische Universität Dresden, CRTD - Center for Regenerative Therapies TU Dresden and Center for Healthy Aging, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Freytag V; Institute of Anatomy and Experimental Morphology, Center for Experimental Medicine, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Germany., Haider MT; Institute of Anatomy and Experimental Morphology, Center for Experimental Medicine, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Germany., Fjeldbo CS; Department of Radiation Biology, Oslo University Hospital, Oslo, Norway., Di Gaetano S; OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany., Schwarz FM; OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology-OncoRay, Dresden, Germany.; German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany., Patil S; OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology-OncoRay, Dresden, Germany.; German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany., Borkowetz A; Department of Urology, University Hospital and Faculty of Medicine, Technische Universität Dresden, Dresden, Germany., Erb HHH; Department of Urology, University Hospital and Faculty of Medicine, Technische Universität Dresden, Dresden, Germany., Baniahmad A; Institute of Human Genetics, Jena University Hospital, Friedrich Schiller University, Jena, Germany., Mircetic J; OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.; German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany., Lyng H; Department of Radiation Biology, Oslo University Hospital, Oslo, Norway.; Department of Physics, University of Oslo, Oslo, Norway., Löck S; OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.; German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), partner site Dresden: German Cancer Research Center (DKFZ), Heidelberg; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Linge A; OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.; German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), partner site Dresden: German Cancer Research Center (DKFZ), Heidelberg; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Lange T; Institute of Anatomy and Experimental Morphology, Center for Experimental Medicine, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Germany.; Institute of Anatomy I, Cancer Center Central Germany, Jena, University Hospital, Jena, Germany., Knopf F; Technische Universität Dresden, CRTD - Center for Regenerative Therapies TU Dresden and Center for Healthy Aging, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Wielockx B; Institute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, Dresden, Germany., Krause M; OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology-OncoRay, Dresden, Germany.; German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), partner site Dresden: German Cancer Research Center (DKFZ), Heidelberg; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Perner S; Institute of Pathology, University Hospital Schleswig-Holstein, Luebeck, Germany; Pathology, Research Center Borstel, Leibniz Lung Center, Borstel, Germany., Dubrovska A; OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology-OncoRay, Dresden, Germany.; German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), partner site Dresden: German Cancer Research Center (DKFZ), Heidelberg; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.

Publikováno v: Theranostics [Theranostics] 2024 Jan 01; Vol. 14 (2), pp. 714-737. Date of Electronic Publication: 2024 Jan 01 (Print Publication: 2024).

Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance.

Autor: Chakravarthy A; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Reddin I; Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK., Henderson S; UCL Cancer Institute, Bill Lyons Informatics Centre, University College London, London, UK., Dong C; School of Biosciences, Division of Natural Sciences, University of Kent, Canterbury, UK., Kirkwood N; School of Biosciences, Division of Natural Sciences, University of Kent, Canterbury, UK., Jeyakumar M; School of Biosciences, Division of Natural Sciences, University of Kent, Canterbury, UK., Rodriguez DR; School of Biosciences, Division of Natural Sciences, University of Kent, Canterbury, UK., Martinez NG; School of Biosciences, Division of Natural Sciences, University of Kent, Canterbury, UK., McDermott J; UCL Cancer Institute, University College London, London, UK., Su X; MD Anderson Cancer Center, Houston, TX, USA., Egawa N; Department of Pathology, University of Cambridge, Cambridge, UK., Fjeldbo CS; Department of Radiation Biology, Oslo University Hospital, Oslo, Norway., Skingen VE; Department of Radiation Biology, Oslo University Hospital, Oslo, Norway., Lyng H; Department of Radiation Biology, Oslo University Hospital, Oslo, Norway.; Department of Physics, University of Oslo, Oslo, Norway., Halle MK; Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway., Krakstad C; Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway., Soleiman A; INNPATH, Institute of Pathology, Tirol Kliniken Innsbruck, Innsbruck, Austria., Sprung S; Institute of Pathology, Medical University of Innsbruck, Innsbruck, Austria., Lechner M; UCL Cancer Institute, University College London, London, UK., Ellis PJI; School of Biosciences, Division of Natural Sciences, University of Kent, Canterbury, UK., Wass M; School of Biosciences, Division of Natural Sciences, University of Kent, Canterbury, UK., Michaelis M; School of Biosciences, Division of Natural Sciences, University of Kent, Canterbury, UK., Fiegl H; Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Innsbruck, Austria., Salvesen H; Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway., Thomas GJ; Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK., Doorbar J; Department of Pathology, University of Cambridge, Cambridge, UK., Chester K; UCL Cancer Institute, University College London, London, UK. k.chester@ucl.ac.uk., Feber A; Centre for Molecular Pathology, Royal Marsden Hospital Trust, London, UK. a.feber@ucl.ac.uk.; Division of Surgery and Interventional Science, University College London, London, UK. a.feber@ucl.ac.uk., Fenton TR; Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. t.r.fenton@soton.ac.uk.; School of Biosciences, Division of Natural Sciences, University of Kent, Canterbury, UK. t.r.fenton@soton.ac.uk.; Institute for Life Sciences, University of Southampton, Southampton, UK. t.r.fenton@soton.ac.uk.

Publikováno v: Nature communications [Nat Commun] 2022 Oct 07; Vol. 13 (1), pp. 5818. Date of Electronic Publication: 2022 Oct 07.

miR-200a/b/-429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer.

Autor: Nilsen A; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Norway., Hillestad T; Department of Core Facilities, Norwegian Radium Hospital, Oslo University Hospital, Norway., Skingen VE; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Norway., Aarnes EK; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Norway., Fjeldbo CS; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Norway., Hompland T; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Norway.; Department of Core Facilities, Norwegian Radium Hospital, Oslo University Hospital, Norway., Evensen TS; Department of Core Facilities, Norwegian Radium Hospital, Oslo University Hospital, Norway., Stokke T; Department of Core Facilities, Norwegian Radium Hospital, Oslo University Hospital, Norway., Kristensen GB; Department of Gynecological Oncology, Norwegian Radium Hospital, Oslo University Hospital, Norway.; Institute of Cancer Genetics and Informatics, Oslo University Hospital, Norway., Grallert B; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Norway., Lyng H; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Norway.; Department of Physics, University of Oslo, Norway.

Publikováno v: Molecular oncology [Mol Oncol] 2022 Mar; Vol. 16 (6), pp. 1402-1419. Date of Electronic Publication: 2022 Feb 15.

MRI Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer.

Autor: Hillestad T; Department of Core Facilities, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Hompland T; Department of Core Facilities, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Fjeldbo CS; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Skingen VE; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Salberg UB; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Aarnes EK; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Nilsen A; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Lund KV; Department of Radiology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Evensen TS; Department of Core Facilities, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Kristensen GB; Department of Gynecological Oncology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Institute of Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway., Stokke T; Department of Core Facilities, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Lyng H; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. heidi.lyng@rr-research.no.; Department of Physics, University of Oslo, Oslo, Norway.

Publikováno v: Cancer research [Cancer Res] 2020 Sep 15; Vol. 80 (18), pp. 3993-4003. Date of Electronic Publication: 2020 Jun 30.